Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) [Phase 3]

View source ↗

Summary

This entry describes a phase 3 clinical trial (MK-3475-676/KEYNOTE-676) evaluating pembrolizumab in combination with intravesical Bacillus Calmette-Guérin for h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: High-risk Non-muscle Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING